Valcyte (valganciclovir)

Valcyte works by preventing the spread of cytomegalovirus (CMV) disease, or slowing the growth of CMV. It is indicated for the treatment of CMV retinitis in adult patients with acquired immunodeficiency syndrome (AIDS), and the prevention of CMV disease in adult and paediatric solid organ transplant patients who are at risk of infection.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeCovid-19Pharma solutionsRoche careersMedia libraryAnnual Report 2023Privacy policyLegal statement